FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2753248752> ?p ?o ?g. }

• W2753248752 abstract "Background In patients (pts) with polyarticular-course juvenile idiopathic arthritis (pJIA), SC abatacept (ABA) 125 mg weekly has a similar pharmacokinetic profile, therapeutically equivalent efficacy and comparable safety to IV ABA 10 mg/kg every 4 weeks.1 Although some data on paediatric pt-reported outcomes (PRO) have been published for IV ABA,2 PRO data following treatment with SC ABA have not. Objectives This analysis examined the effect of SC ABA treatment on PROs (activities of daily living [ADL] limitation questionnaire of parent/caregiver, childhood HAQ [CHAQ]-DI, and parent global assessment of overall pt well-being [PaGA]) in 6–17-year pts with active pJIA in a Phase III trial (NCT01844518). Methods Pts with pJIA aged 2–17 years with an inadequate response/intolerance to ≥1 DMARD were enrolled in this single-arm, open-label study and received SC ABA weekly for 4 months based on body weight tier (10– 50 kg [125 mg ABA]). JIA-ACR 30 criteria (ACR Pediatric 30) responders at Month 4 could receive ABA for another 20 months. For the 6–17-year cohort reported here, ADL limitation questionnaire of parent/caregiver (mean [SD] number of days [D] of parental/caregiver missed activity, paid care and missed school [absolute values per month and percentage of D missed per month relative to an assumed average of 20 school D/month]); CHAQ-DI (0–3 scale across 8 domains of disability component); and PaGA (0–100 mm visual analogue scale) were evaluated. Results Baseline characteristics of the 173 pts with pJIA from the 6–17-year cohort were: median (min, max) age, 13.0 (6.0, 17.0) years; median (min, max) number of active joints, 10.0 (2.0, 42.0); 78.6% of pts used MTX (median dose: 11.6 mg/m2/week); and 26.6% were with prior biologic failure. All ADL limitation components improved from baseline to D113 (Month 4); these improvements were largely maintained at D309 (Figure). Relative percentage D missed from school decreased from 15% (D1) to 5.5% (D309, Figure D). CHAQ-DI and PaGA improved from baseline to D309 (Table). Further 2-year data are pending. Conclusions In this analysis of patients with pJIA aged 6–17 years, SC abatacept demonstrated a beneficial effect on PROs including reductions in activity limitation and disability (CHAQ-DI) and improvement in well-being (PaGA) up to D309. References Lovell D, et al. Arthritis Rheumatol 2016;68(suppl 10): Abstract 948. Ruperto N, et al. Arthritis Care Res 2010;62:1542–51. Disclosure of Interest N. Ruperto Grant/research support from: The G. Gaslini Hospital has received contributions from the following industries for the coordination activity of the PRINTO network: Bristol-Myers Squibb, GlaxoSmithKline, Hoffman-La Roche, Novartis, Pfizer,sanofi-aventis, Schwarz Biosciences, Abbott, Francesco Angelini S.P.A., Sobi, Merck Serono, Consultant for: AbbVie, Amgen, Biogen Idec, Alter, AstraZeneca, Baxalta Biosimilars, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo Bioscience, EMD Serono, Hoffman-La Roche, Italfarmaco, Janssen, MedImmune, Medac, Novartis, Novo Nordisk, Pfizer, sanofi-aventis, Servier, Takeda, UCB Biosciences GmbH, Speakers bureau: AbbVie, Amgen, Biogen Idec, Alter, AstraZeneca, Baxalta Biosimilars, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo Bioscience, EMD Serono, Hoffman-La Roche, Italfarmaco, Janssen, MedImmune, Medac, Novartis, Novo Nordisk, Pfizer, sanofi-aventis, Servier, Takeda, UCB Biosciences GmbH, H. Brunner: None declared, N. Tzaribachev: None declared, G. Vega-Cornejo: None declared, I. Louw: None declared, J. Anton Grant/research support from: Bristol-Myers Squibb, Novartis, Pfizer, AbbVie, GSK, Sobi, Roche, Alexion, Sanofi, Genzyme, Consultant for: Novartis, Sobi, Roche, Gebro, Pfizer, AbbVie, Alexion, Speakers bureau: Novartis, AbbVie, Pfizer, Sobi, Roche, Gebro, D. Viola: None declared, I. Foeldvari: None declared, V. Keltsev: None declared, D. Kingsbury: None declared, C. Wouters: None declared, B. Lauwerys: None declared, E. Alemao Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, R. Wong Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, M. Nys Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, S. Banerjee Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, A. Martini: None declared, D. Lovell Grant/research support from: National Institutes of Health, NIAMS, Consultant for: AstraZeneca, Bristol-Myers Squibb, AbbVie, Pfizer, Roche, Novartis, UBC, Forest Research Institute, Horizon, Johnson & Johnson, Biogen, Takeda, Genentech, GlaxoSmithKline, Boehringer Ingelheim, Celgene, Janssen, Speakers bureau: Genentech" @default.
• W2753248752 created "2017-09-15" @default.
• W2753248752 creator A5020603336 @default.
• W2753248752 creator A5022458571 @default.
• W2753248752 creator A5024977051 @default.
• W2753248752 creator A5025765870 @default.
• W2753248752 creator A5027612338 @default.
• W2753248752 creator A5034764312 @default.
• W2753248752 creator A5037058226 @default.
• W2753248752 creator A5040793104 @default.
• W2753248752 creator A5043757979 @default.
• W2753248752 creator A5048628555 @default.
• W2753248752 creator A5054063371 @default.
• W2753248752 creator A5055162371 @default.
• W2753248752 creator A5055874104 @default.
• W2753248752 creator A5058194613 @default.
• W2753248752 creator A5061319680 @default.
• W2753248752 creator A5072290078 @default.
• W2753248752 creator A5074039933 @default.
• W2753248752 creator A5082661470 @default.
• W2753248752 date "2017-06-01" @default.
• W2753248752 modified "2023-09-28" @default.
• W2753248752 title "OP0058 Improvement in patient-reported outcomes in patients with polyarticular-course juvenile idiopathic arthritis and inadequate response to biologic or non-biologic disease-modifying antirheumatic drugs treated with sc abatacept" @default.
• W2753248752 doi "https://doi.org/10.1136/annrheumdis-2017-eular.2236" @default.
• W2753248752 hasPublicationYear "2017" @default.
• W2753248752 type Work @default.
• W2753248752 sameAs 2753248752 @default.
• W2753248752 citedByCount "0" @default.
• W2753248752 crossrefType "proceedings-article" @default.
• W2753248752 hasAuthorship W2753248752A5020603336 @default.
• W2753248752 hasAuthorship W2753248752A5022458571 @default.
• W2753248752 hasAuthorship W2753248752A5024977051 @default.
• W2753248752 hasAuthorship W2753248752A5025765870 @default.
• W2753248752 hasAuthorship W2753248752A5027612338 @default.
• W2753248752 hasAuthorship W2753248752A5034764312 @default.
• W2753248752 hasAuthorship W2753248752A5037058226 @default.
• W2753248752 hasAuthorship W2753248752A5040793104 @default.
• W2753248752 hasAuthorship W2753248752A5043757979 @default.
• W2753248752 hasAuthorship W2753248752A5048628555 @default.
• W2753248752 hasAuthorship W2753248752A5054063371 @default.
• W2753248752 hasAuthorship W2753248752A5055162371 @default.
• W2753248752 hasAuthorship W2753248752A5055874104 @default.
• W2753248752 hasAuthorship W2753248752A5058194613 @default.
• W2753248752 hasAuthorship W2753248752A5061319680 @default.
• W2753248752 hasAuthorship W2753248752A5072290078 @default.
• W2753248752 hasAuthorship W2753248752A5074039933 @default.
• W2753248752 hasAuthorship W2753248752A5082661470 @default.
• W2753248752 hasBestOaLocation W27532487521 @default.
• W2753248752 hasConcept C115961737 @default.
• W2753248752 hasConcept C126322002 @default.
• W2753248752 hasConcept C159110408 @default.
• W2753248752 hasConcept C1862650 @default.
• W2753248752 hasConcept C2777077863 @default.
• W2753248752 hasConcept C2779338263 @default.
• W2753248752 hasConcept C2779605438 @default.
• W2753248752 hasConcept C2779951463 @default.
• W2753248752 hasConcept C2780653079 @default.
• W2753248752 hasConcept C2910384678 @default.
• W2753248752 hasConcept C512399662 @default.
• W2753248752 hasConcept C54355233 @default.
• W2753248752 hasConcept C71924100 @default.
• W2753248752 hasConcept C72563966 @default.
• W2753248752 hasConcept C79544238 @default.
• W2753248752 hasConcept C86803240 @default.
• W2753248752 hasConceptScore W2753248752C115961737 @default.
• W2753248752 hasConceptScore W2753248752C126322002 @default.
• W2753248752 hasConceptScore W2753248752C159110408 @default.
• W2753248752 hasConceptScore W2753248752C1862650 @default.
• W2753248752 hasConceptScore W2753248752C2777077863 @default.
• W2753248752 hasConceptScore W2753248752C2779338263 @default.
• W2753248752 hasConceptScore W2753248752C2779605438 @default.
• W2753248752 hasConceptScore W2753248752C2779951463 @default.
• W2753248752 hasConceptScore W2753248752C2780653079 @default.
• W2753248752 hasConceptScore W2753248752C2910384678 @default.
• W2753248752 hasConceptScore W2753248752C512399662 @default.
• W2753248752 hasConceptScore W2753248752C54355233 @default.
• W2753248752 hasConceptScore W2753248752C71924100 @default.
• W2753248752 hasConceptScore W2753248752C72563966 @default.
• W2753248752 hasConceptScore W2753248752C79544238 @default.
• W2753248752 hasConceptScore W2753248752C86803240 @default.
• W2753248752 hasLocation W27532487521 @default.
• W2753248752 hasOpenAccess W2753248752 @default.
• W2753248752 hasPrimaryLocation W27532487521 @default.
• W2753248752 hasRelatedWork W2342222516 @default.
• W2753248752 hasRelatedWork W2410431210 @default.
• W2753248752 hasRelatedWork W2552326957 @default.
• W2753248752 hasRelatedWork W2555402540 @default.
• W2753248752 hasRelatedWork W2557000498 @default.
• W2753248752 hasRelatedWork W2754241019 @default.
• W2753248752 hasRelatedWork W2754249426 @default.
• W2753248752 hasRelatedWork W2754803002 @default.
• W2753248752 hasRelatedWork W2755795982 @default.
• W2753248752 hasRelatedWork W2909246594 @default.
• W2753248752 hasRelatedWork W2910426771 @default.
• W2753248752 hasRelatedWork W2951669248 @default.
• W2753248752 hasRelatedWork W3045160920 @default.
• W2753248752 hasRelatedWork W3097716538 @default.
• W2753248752 hasRelatedWork W3164248325 @default.
• W2753248752 hasRelatedWork W3164301040 @default.
• W2753248752 hasRelatedWork W3164521912 @default.

• next